Home / Market News / $OGN

$OGN news and market catalysts

The 7 most recent market catalysts affecting $OGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 0 high impact 2 bullish 1 bearish Pharmaceuticals
Nov 8, 2026 Corporate Catalyst Bullish Impact 55
Organon Presents Real-World Evidence on HADLIMA Biosimilar Switch in VA Healthcare System
Organon disclosed real-world data from the VA Healthcare System demonstrating the successful transition of over 16,000 patients from the originator drug HUMIRA to its biosimilar, H…
Oct 30, 2026 Corporate Catalyst Bearish Impact 75
Organon Reports Third Quarter 2026 Financial Results
Organon & Co. announced its third-quarter 2026 financial results, revealing a 2% year-over-year revenue decrease. Despite this, the company saw an increase in net income and an imp…
Oct 28, 2026 Energy/Commodity Neutral Impact 55
Orogen Royalties Announces Drilling Results from Maggie Creek Gold Project
Orogen Royalties announced that its partner, U.S. Gold Corp., completed a two-hole drilling program at the Maggie Creek gold project. This is a routine update on exploration activi…
Oct 16, 2026 Corporate Catalyst Neutral Impact 55
Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting
This 8-K filing discloses that Organon's licensed MIUDELLA IUD will have its 6-year interim Phase 3 results presented at a medical conference in 2026. The data presented, including…
Sep 28, 2026 Corporate Catalyst Bullish Impact 55
Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis
Organon Canada has announced the approval and immediate availability of NDUVRA (tapinarof cream) for the treatment of moderate to severe atopic dermatitis in Canada. This is a posi…
Aug 11, 2026 Corporate Catalyst Neutral Impact 65
Organon Announces Enrollment Now Open For MIUDELLA REMS Certification Program Ahead Of Copper IUD's US Launch In Late 2026
This headline is a moderate corporate catalyst for Organon, indicating successful navigation of regulatory hurdles for its MIUDELLA copper IUD. While the launch is still over two y…
Jul 24, 2026 Corporate Catalyst Neutral Impact 55
Organon To Present Results From Post Hoc Analysis Of Pooled Data From Phase 3 Pivotal Trials, ADORING 1 And ADORING 2, Evaluating VTAMA Cream Versus Vehicle At 2026 SPD Annual Meeting
Organon presented new, detailed data from a post-hoc analysis of its Phase 3 trials for VTAMA cream at a pediatric dermatology meeting. This filing highlights the consistent effica…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.